Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. Am J Clin Oncol 1987 Jun;10(3):216-8
Date
06/01/1987Pubmed ID
3496002DOI
10.1097/00000421-198706000-00008Scopus ID
2-s2.0-0023275737 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
Thirteen patients with metastatic colorectal adenocarcinoma underwent treatment with continuous ambulatory 5-fluorouracil (5-FU) infusion 300 mg/m2/day and intermittent bolus methotrexate (MTX) (200 mg/m2) with calcium leucovorin (LCV) 10 mg/m2 orally every 6 h X four to eight doses given 24 h after MTX. Although MTX administration was planned every 14 days, the average time between treatments exceeded 19 days (range 14-42) because of excessive toxicity. All patients experienced toxicity at some time in their treatment course, requiring interruption of 5-FU infusion in 12 of 13 patients. Significant toxicities included stomatitis (13 of 13 patients), hand-foot syndrome (8 of 13 patients), and diarrhea (3 of 13 patients). Toxicity did not appear to be minimized by attenuation of MTX and/or 5-FU dosage or by increasing the dose and/or duration of LCV. At this dosage schedule the addition of MTX/LCV to 5-FU infusion results in excessive and unacceptable toxicity and does not appear to improve treatment results.
Author List
Hansen RM, Quebbeman EJ, Ritch PS, Frick J, Anderson TAuthor
Edward J. Quebbeman MD Emeritus Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenocarcinomaAdministration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Colonic Neoplasms
Drug Administration Schedule
Drug Evaluation
Drug Synergism
Female
Fluorouracil
Humans
Infusions, Intravenous
Leucovorin
Male
Methotrexate
Middle Aged
Rectal Neoplasms
